Premium
Duavive HRT: conjugated oestrogens with bazedoxifene
Author(s) -
Chaplin Steve
Publication year - 2016
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1525
Subject(s) - medicine , postmenopausal women , selective estrogen receptor modulator , adverse effect , uterus , conjugated system , gynecology , oncology , endocrinology , estrogen receptor , cancer , breast cancer , chemistry , organic chemistry , polymer
Duavive is a new oral HRT formulation containing conjugated oestrogens and the selective oestrogen‐receptor modulator bazedoxifene and is indicated for the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus who cannot take progestogencontaining therapy. This article discusses its properties, efficacy and adverse effects.